Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma.
Read the full article on WikipediaStage IV (metastatic) Merkel Cell Carcinoma Clinical criteria: Treatment Phase: Continuing treatment The treatment must be the sole PBS-subsidised therapy for this condition, AND Patient must have previously received PBS-subsidised treatment with this drug for this condition, AND Patient must not have developed disease progression while being treated with this drug for this condition, AND The treatment must not exceed a maximum dose of 10 mg per kg every 2 weeks under this restriction; OR The treatment must not exceed a dose of 800 mg every 2 weeks under this restriction.
Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer Clinical criteria: Treatment Phase: Maintenance therapy - Initial treatment Patient must have received first-line platinum-based chemotherapy, AND Patient must not have progressive disease following first-line platinum-based chemotherapy, AND Patient must have a WHO performance status of 0 or 1, AND The treatment must be the sole PBS-subsidised therapy for this condition, AND Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for this condition.
“Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Formation of a PD-1/PD-L1 receptor/ligand complex leads to inhibition of CD8+ T cells, and therefore inhibition of an immune reaction. Immunotherapy aims at ceasing this immune blockage by blocking those receptor ligand pairs. In the case of avelumab, the formation of PD-1/PDL1 ligand pairs is blocked and CD8+ T cell immune response should be increased. PD-1 itself has also been a target for immunotherapy.”
“6.1 days”
Working under the parallel aged-care framework? Aged-care equivalent →